β-Lactamase-Producing, Ciprofloxacin-Resistant Neisseria meningitidis Isolated From a 5-Month-Old Boy in the United States.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
03 Apr 2021
Historique:
received: 13 05 2020
accepted: 08 07 2020
pubmed: 4 8 2020
medline: 19 8 2021
entrez: 4 8 2020
Statut: ppublish

Résumé

Worldwide, there have been few reports of β-lactamases causing penicillin resistance in Neisseria meningitidis. The first known case of disease in the United States due to a β-lactamase-producing, ciprofloxacin-resistant N. meningitidis was recently identified. This has potential implications on standard laboratory testing and empiric management of meningococcal disease.

Identifiants

pubmed: 32743638
pii: 5876038
doi: 10.1093/jpids/piaa085
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ciprofloxacin 5E8K9I0O4U

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

379-381

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Gillian Taormina (G)

Children's National Hospital, Division of Infectious Diseases, Washington, District of Columbia, USA.

Joseph Campos (J)

Children's National Hospital, Department of Microbiology, Washington, District of Columbia, USA.

John Sweitzer (J)

Maryland Department of Health, Baltimore, Maryland, USA.

Adam C Retchless (AC)

Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Kristy Lunquest (K)

Maryland Department of Health, Baltimore, Maryland, USA.

Lucy A McNamara (LA)

Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Natashia Reese (N)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Maria Karlsson (M)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Benjamin Hanisch (B)

Children's National Hospital, Division of Infectious Diseases, Washington, District of Columbia, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH